Envista Holdings Corporation (NVST)
NEUTRAL基本面
55
价格
$27.47
市值
$4.40B
第一部分 · 这家公司值多少
概览
Envista makes the products dentists and orthodontists use every day: dental implants, clear aligners and orthodontic brackets, plus the equipment and consumables — imaging systems, drills, cements, infection-control supplies — that keep a dental office running. It sells through its own sales force and a network of dealers to over 130 countries, serving both specialists who place implants and general practitioners who handle routine care. More than half its sales come from outside the United States.
盈利方式
Envista books revenue when it ships implants, aligners, equipment or consumables to dealers and dental practices; consumables and implants are recurring, replenished purchases, while imaging systems and other capital equipment are one-off, lumpier sales tied to a practice's investment cycle. Its two segments split roughly two-thirds specialty products (implants, orthodontics) to one-third equipment and consumables, and its largest single distributor, Henry Schein, alone channels about 12% of total sales to end customers.
分部营收
Dental implant systems, regenerative products and orthodontic brackets, aligners and lab products for specialists and general dentists.
Dental imaging systems, endodontic equipment, restorative materials, cements and infection-prevention supplies used in daily practice.
护城河
规模效应 · 狭窄Envista describes itself as running one of the largest customer-facing sales teams in the dental industry, backed by a global dealer network reaching over 130 countries. That distribution scale is hard for smaller rivals to match, but the underlying implant and equipment categories are competitive and price-sensitive, so the advantage is narrow rather than a lock on the market.
需求驱动因素
中度周期性Routine dental consumables track fairly steady patient visit volumes, but elective procedures like implants and big-ticket equipment purchases are more discretionary and get postponed when practices or patients tighten spending. The mix of the two makes overall demand more resilient than typical consumer discretionary goods, but not fully immune to economic cycles.
主要风险
- Distributor dependence — A substantial portion of sales flows through a limited number of distributors, chiefly Henry Schein, with no assurance any of them will keep purchasing at current levels or that lost volume could be quickly replaced.
- Distributor inventory swings — The company relies on predictions of distributor and customer inventory levels to plan production; when those inventories build or run down differently than expected, reported results can diverge sharply from underlying demand.
- Acquisition and divestiture risk — Envista routinely acquires and divests businesses to fit its portfolio strategy, and warns that earn-outs, indemnification obligations, goodwill impairments and unsatisfied deal conditions could all produce unpredictable financial results.
客户集中度
主要客户占营收的12%
Henry Schein, the company's largest distributor, accounted for approximately 12% of sales in 2025 and is expected to remain the top contributor for the foreseeable future, without a master distribution agreement guaranteeing that relationship.
看多理由
Buyers argue that Envista's scale in global dental distribution and its position across both the specialist implant market and everyday consumables give it a resilient, recurring revenue base that should benefit as dental procedure volumes recover outside the U.S.
看空理由
Sellers fear that heavy reliance on a handful of distributors, led by Henry Schein, leaves Envista exposed to a single relationship it does not fully control, and that elective procedure volumes remain vulnerable if patients keep deferring discretionary dental work.
Written by the editors, published on 2026年8月18日
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
资产负债表与流动性
营收
$2.86B
最近12个月(截至2026/7/3)
净利润
$95M
最近12个月(截至2026/7/3)
自由现金流
$230M
股东权益合计
$3.11B
负债合计
$2.57B
流动比率
2.43
利息覆盖率
-
债务/EBITDA
4.78
每股收益
营收与净利润
自由现金流
收入构成
历史财务表
利润率变化
债务变化
债务负担有多重
增长一览表
增长 — 营业收入
公允价值估算
公允价值
$24.42
当前价格
$27.47
安全边际
-12.5%
公允价值区间
$15.88 - $32.97
估算方法
估值指标
市盈率(P/E)
47.14
ROE
1.5%
市净率(P/B)
1.43
P/FCF
17.70
毛利率
55.2%
ROIC
4.5%
盈利能力雷达图
Value Creation (Economic Moat)
ROIC
4.5%
WACC
6.9%
ROIC − WACC
-2.4 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
基本面分析标准
通过(17)
- Gross Margin 55.2%
- P/FCF 17.70
- P/B Ratio 1.43
- Debt/Equity ratio
- Operating Margin 9.6%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- Revenue Growth 5Y 7.1%
- Analyst Consensus 55% Buy
- Earnings Surprise avg 15.7%
- Earnings Quality (OCF/NI) 3.19
- Share Dilution -2.5%
- Net Margin Trend 3.3% vs 2.1%
- Piotroski F-Score 7/9
未通过(9)
- EPS shows upward trend
- EPS CAGR -23.35%
- Price CAGR -1.22%
- ROIC 4.5%
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Fairly valued)
- ROE 3.1%
- PEG Ratio 7.29
不可用(2)
- Dividend Payout NaN%
- Interest Coverage
Piotroski F-评分
财务状况强健
盈利质量
高质量:盈利有现金流支撑
股权稀释
正在回购股份,对股东友好
公司治理
管理团队
| 姓名 | 职位 | 年龄 |
|---|---|---|
| Mr. Eric D. Hammes | Senior VP & CFO | 50 |
| Mr. Mark E. Nance J.D. | Senior VP, General Counsel & Secretary | 56 |
| Mr. Robert Befidi Jr. | Senior VP & President of Diagnostics | 50 |
| Ms. Veronica Acurio | Senior VP & President of Orthodontics | 54 |
| Mr. Coree Thomas | VP & Chief Accounting Officer | 47 |
| Mr. Andrew Chen | Chief Information Officer | - |
| Mr. Jim Gustafson | Vice President of Investor Relations | - |
| Paul Sumilas | Chief Compliance Officer | - |
| Mr. Mischa M. Reis | Senior Vice President of Strategy & Corporate Development | 52 |
| Mr. Suraj Satpathy | Chief Human Resources officer | - |
审计风险
2
董事会风险
2
薪酬风险
4
股东权利风险
5
第二部分 · 价格与买入时机
这一部分不判断公司是否值得拥有:它帮助你在基本面说服你之后,选择何时买入。包含:技术分析、潜力、历史回撤、Gamma 敞口。
Latest News
Recent headlines for NVST, sourced from Markets Gazette.